- Home
- CLGN vs DYAI Comparison
CLGN vs DYAI Comparison
Compare CLGN & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- DYAI
- Stock Information
- Founded
- CLGN 2004
- DYAI 1979
- Country
- CLGN Israel
- DYAI United States
- Employees
- CLGN N/A
- DYAI N/A
- Industry
- CLGN Industrial Specialties
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLGN Health Care
- DYAI Health Care
- Exchange
- CLGN Nasdaq
- DYAI Nasdaq
- Market Cap
- CLGN 33.8M
- DYAI 30.2M
- IPO Year
- CLGN N/A
- DYAI 2004
- Fundamental
- Price
- CLGN $2.66
- DYAI $0.97
- Analyst Decision
- CLGN Strong Buy
- DYAI Strong Buy
- Analyst Count
- CLGN 2
- DYAI 1
- Target Price
- CLGN $11.50
- DYAI $6.00
- AVG Volume (30 Days)
- CLGN 30.5K
- DYAI 119.9K
- Earning Date
- CLGN 08-20-2025
- DYAI 11-11-2025
- Dividend Yield
- CLGN N/A
- DYAI N/A
- EPS Growth
- CLGN N/A
- DYAI N/A
- EPS
- CLGN N/A
- DYAI N/A
- Revenue
- CLGN $2,402,000.00
- DYAI $4,135,078.00
- Revenue This Year
- CLGN $1,617.28
- DYAI $34.23
- Revenue Next Year
- CLGN $83.54
- DYAI $19.57
- P/E Ratio
- CLGN N/A
- DYAI N/A
- Revenue Growth
- CLGN 248.62
- DYAI 129.20
- 52 Week Low
- CLGN $1.31
- DYAI $0.71
- 52 Week High
- CLGN $5.00
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- CLGN 52.88
- DYAI 54.94
- Support Level
- CLGN $2.38
- DYAI $0.95
- Resistance Level
- CLGN $2.77
- DYAI $1.01
- Average True Range (ATR)
- CLGN 0.18
- DYAI 0.05
- MACD
- CLGN -0.02
- DYAI 0.01
- Stochastic Oscillator
- CLGN 47.46
- DYAI 74.67
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.